Apeloa Pharmaceutical Co.,Ltd
Shenzhen Stock ExchangeTotal Valuation
Apeloa Pharmaceutical Co.,Ltd carries a market capitalization of 20.61B, placing it among publicly traded companies globally. Its enterprise value stands at 18.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.61B |
| Enterprise Value | 18.61B |
Share Statistics
Apeloa Pharmaceutical Co.,Ltd currently has 1.16B shares outstanding.
| Shares Outstanding | 1.16B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Apeloa Pharmaceutical Co.,Ltd trades at a trailing price-to-earnings ratio of 27.37. The price-to-sales ratio is 2.87, and the price-to-book ratio stands at 3.16.
| PE Ratio | 27.37 |
| PS Ratio | 2.87 |
| PB Ratio | 3.16 |
| P/TBV Ratio | 3.33 |
| P/FCF Ratio | 65.27 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Apeloa Pharmaceutical Co.,Ltd trades at an EV/EBITDA multiple of 18.84 and an EV/FCF ratio of 54.76. The EV/Sales ratio of 2.59 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 18.84 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.59 |
| EV / EBITDA | 18.84 |
| EV / EBIT | 18.84 |
| EV / FCF | 54.76 |
Financial Position
Apeloa Pharmaceutical Co.,Ltd maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.46, indicating elevated leverage, while an interest coverage ratio of 35.39 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.55 |
| Quick Ratio | 0.72 |
| Debt / Equity | 24.46 |
| Debt / EBITDA | 1.63 |
| Interest Coverage | 35.39 |
Financial Efficiency
Apeloa Pharmaceutical Co.,Ltd posts a return on equity of 11.53 and a return on invested capital of 10.39.
| Return on Equity (ROE) | 11.53 |
| Return on Assets (ROA) | 6.04 |
| Return on Invested Capital (ROIC) | 10.39 |
| Return on Capital Employed (ROCE) | 10.03 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.34 |
Taxes
Over the trailing twelve months, Apeloa Pharmaceutical Co.,Ltd has paid 131.73M in income taxes, reflecting an effective tax rate of 14.87.
| Income Tax | 131.73M |
| Effective Tax Rate | 14.87 |
Stock Price Statistics
Apeloa Pharmaceutical Co.,Ltd's stock has gained approximately 23.97213% over the past 52 weeks. The 50-day moving average sits at 17.05, while the 200-day moving average is 17.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 23.97213% |
| 50-Day Moving Average | 17.05 |
| 200-Day Moving Average | 17.02 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Apeloa Pharmaceutical Co.,Ltd generated 7.18B in revenue and converted that into 753.93M in net income, yielding earnings per share of 0.65. EBITDA reached 988.13M, while operating income came in at 988.13M.
| Revenue | 7.18B |
| Gross Profit | 2.10B |
| Operating Income | 988.13M |
| Pretax Income | 885.99M |
| Net Income | 753.93M |
| EBITDA | 988.13M |
| EBIT | 988.13M |
| Earnings Per Share (EPS) | 0.65 |
Balance Sheet
Apeloa Pharmaceutical Co.,Ltd holds 3.63B in cash and equivalents against 1.61B in total debt, resulting in a net debt position of -2.10B. Total book value stands at 6.52B, with working capital of 2.81B providing operational flexibility.
| Cash & Cash Equivalents | 3.63B |
| Total Debt | 1.61B |
| Net Debt | -2.10B |
| Equity (Book Value) | 6.52B |
| Book Value Per Share | 5.64 |
| Working Capital | 2.81B |
Cash Flow
After subtracting -316.09M in capital expenditures, free cash flow totaled -316.09M - equivalent to -0.27 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -316.09M |
| Free Cash Flow | -316.09M |
| FCF Per Share | -0.27 |
Margins
Apeloa Pharmaceutical Co.,Ltd operates with a gross margin of 29.22, reflecting its pricing power and cost economics. The operating margin of 13.76 and net profit margin of 10.50 provide insight into operational efficiency.
| Gross Margin | 29.22 |
| Operating Margin | 13.76 |
| Pretax Margin | 12.34 |
| Profit Margin | 10.50 |
| EBITDA Margin | 13.76 |
Dividends & Yields
The company's payout ratio of 57.03 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.37 |
| Dividend Yield | N/A |
| Payout Ratio | 57.03 |
| Shareholder Yield | 1.21 |
| FCF Yield | 1.53 |
Stock Splits
Apeloa Pharmaceutical Co.,Ltd's most recent stock split took place on May 30, 2014 with a 10:13 split ratio.
| Last Split Date | 5/30/2014 |
| Split Ratio | 10:13 |
Scores
Apeloa Pharmaceutical Co.,Ltd posts an Altman Z-Score of 3.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.97 |